Q-omics provides the consensus-scored RPL23AP59 profile across patient tissues and cancer cell-line models. RPL23AP59 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RPL23AP59 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, RPL23AP59 RNA expression shows 6,813 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight STAD, KIRC, and DLBC as cancer lineages where RPL23AP59 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL23AP59 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL23AP59 survival associations across molecular data types. RPL23AP59 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL23AP59 RNA expression–survival associations across cancer types. High RPL23AP59 expression shows unfavorable associations in STAD, TGCT and LUAD, but favorable associations in HNSC, LUSC and CESC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for RPL23AP59 RNA expression.
This table summarizes RPL23AP59 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL23AP59. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL23AP59 shows higher tumor expression in KIRC, LUAD, COAD and LIHC. The KIRC box plot shows higher RPL23AP59 RNA expression in tumor versus normal tissue (log2 FC = +0.138, t-test p < 0.001).
This table shows molecular features associated with RPL23AP59 in patient tissues and cancer cell lines. In patient samples, RPL23AP59 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
